The pathogenesis of the antiphospholipid syndrome

New England Journal of Medicine

Volumn 368, Issue 24, 2013, Pages 2334-2335

  Salem, Chaker Ben ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AMOXICILLIN; CHLOROTHIAZIDE; CHLORPROMAZINE; ETANERCEPT; INFLIXIMAB; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PROCAINAMIDE; PROPYLTHIOURACIL; QUININE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CAUSAL ATTRIBUTION; DRUG USE; HUMAN; LETTER; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; THROMBOSIS;

EID: 84878876899     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1304515     Document Type: Letter

References (4)

1. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368:1033-44.
2. Levy Y, Almog O, Gorshtein A, Shoenfeld Y. The environment and antiphospholipid syndrome. Lupus 2006;15:784-90.
3. Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep 2012;14:71-8.
4. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-61.